Methods:
We have systematically searched the PubMed medical database up till March 27, 2020 using MeSH key words that include Covid-19, coronavirus, hypertension, diabetes, cardiovascular disease, angiotensin receptor blockers, angiotensin converting enzyme inhibitors. We have retrieved all the available literature published in English language on COVID-19 that reported the outcomes in different co-morbidities.
Results:

Hypertension as a significant comorbidity with COVID-19:
The association of hypertension and diabetes in patients with COVID-19 is not unexpected, given the rising prevalence of both of these chronic diseases, globally.
Interestingly, in the pooled data from the ten Chinese studies (n=2209) that have reported the characteristics of comorbidities in patients with  associations of hypertension, diabetes and presence of established cardiovascular disease (CVD) are larger, varying from 15-30% (average 21%), 5-20% (average 11%) and 2-40% (average 7%) respectively (table 1) . Established CVD was also present in nearly 43% in Italian study of 355 patients with COVID-19. Table   summarizes the prevalence of these comorbidities in all available studies to-date in patients with COVID-19 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Hypertension as a prognostic indicator for severity and mortality in COVID-19:
While consistent association of hypertension in patients with COVID-19 across all these studies is unique, the concern which needs serious attention is the increase in mortality. Two Chinese studies have worked in this direction to-date. [11] . It should be noted however, that neither of these studies were adjusted for all confounding variables. Nevertheless, a study of 187 patients with COVID-19, Guo et al reported nearly a twice increase in mortality in patients with established CVD and raised troponin T (TnT) compared to patients without CVD and raised TnT (69.4% vs. 37.5% respectively) [14] .
The Chinese Center for Disease Control and Prevention in a summary report of COVID-19 reported a case fatality rate (CFR) of 2.3% (1023 deaths among 44,672 confirmed cases). However, CFR was elevated to 6.0% for hypertension, 7.3% for diabetes, and 10.5% for presence of CVD [15] . Unsurprisingly, based on the above findings, researchers have recently proposed that the course of treatment and prognosis of COVID-19 should be stratified based on the absence or presence of co-morbidities in to type A, B and C. Type A denotes COVID-19 patients with pneumonia but without comorbidities, Type B denotes COVID-19 pneumonia and comorbidities whereas, Type C denotes COVID-19 patients with multi-organ dysfunction [16] .
Nonetheless, it still remains unclear whether these increased association of hypertension with COVID-19 and heightened risk of mortality is directly related to hypertension or other associated comorbidities, anti-hypertensive treatment. There has been a growing concern that this association with hypertension and or CVD may be confounded by the treatment with certain antihypertensive medications such as RASB. Although a recent paper has proposed to stop RASB and suggested to replace it with the calcium channel blocker while treating hypertension in patients with COVID-19 [17] , this hypothesis has been questioned by several other colleagues [18] [19] [20] [21] [22] .
Role of Renin Angiotensin System and its Inhibitors in SARS CoV2 Infection:
The infected patients [28] . There is a possibility that similar variations or polymorphisms in ACE 2 could affect the viral entry and disease course. Polymorphisms of ACE2 gene have been identified; however, there is no evidence that they affect susceptibility to or severity of SARS CoV2 infection [29] . A recent study found differential ACE2 gene expression in human lung tissue with no racial/gender differences, but a higher gene expression in lungs of smokers compared to non-smokers, which could explain the higher risk of infection in smokers [30] .
Physiological role of ACE-2 and its relationship with coronavirus infection:
The role of ACE2 on vascular bed is opposite to that of angiotensin converting enzyme (ACE). ACE converts angiotensin I to angiotensin II, which is a vasoconstrictor. ACE2 converts angiotensin II to angiotensin (1-7) which causes vasodilatation after binding to the Mas receptor in the vascular bed [31] .
Downregulation of ACE2 was observed in animal models of lung injury induced by SARS CoV [32] . Recombinant ACE2 improved pulmonary blood flow and oxygenation in animals with lung injury, indicating that ACE2 may be the main determinant of lung injury caused by SARS CoV [33] . However, there is lack of human data except a small study in 10 patients with acute respiratory distress syndrome which showed that recombinant ACE2 was well tolerated and led to an increase in angiotensin (1-7) [34] .
Effects of ACE Inhibitors and Angiotensin Receptor Blockers:
There has been considerable interest regarding the role of RAS blockers in COVID-19 infection. Both benefit and harm have been postulated. Figure   illustrates the interactions between the effect of RASB and COVID-19. a) Rationale and Evidence for Harm: There is evidence that ACE2 expression increases with the use of ACE inhibitors and ARB, especially in heart and kidney [35, 36] . This has raised a theoretical concern that by increasing ACE2 expression, ACEIs and ARBs could facilitate the entry of virus into the host cell and increase the chances of infection or its severity [17] . Also, there is increased ACE2 expression in elderly [37] . To what extent this predisposes the elderly to infection with SARSCoV2 is not known. In a study of 187 patients with COVID-19, Guo et al reported an increased trend in mortality with those receiving RASB compared to those not receiving. Mortality was 36.8% (6 of 19) and 25.6% (43 of 168) in patients with or without RASB, respectively [14] . Indeed, increased association and heightened mortality with COVID-19 have been observed consistently across the studies in elderly, hypertensive, diabetics and known CVD; however, it is not exactly known whether it has any causal relation with the use of RASB or these subgroups are more on RASB due to these illness, compared to the rest of population. Moreover, there is no solid evidence to back this concern either in COVID-19 or in infection by other coronaviruses. b) Rationale and Evidence for Benefit: As discussed above, increasing ACE2 levels in coronavirus infection could reduce lung injury. In an experimental study with mice, Kuba et al found that losartan showed significantly diminished lung injury and pulmonary edema after acid aspiration-induced acute lung injury (with addition of SARS-CoV spike protein) compared to placebo [32] . Similarly, severe lung injury and pulmonary edema were prevented by both recombinant human ACE2 infusions or losartan in ACE2-knockout mice [38] . Mice with coronavirus induced lung injury showed improvement when treated with losartan [39] . Moreover, a retrospective analysis found reduced rates of death and endotracheal intubation in patients with viral pneumonia who were continued on ACE inhibitors [40] . Treatment with ARBs was reported to reduce mortality in Ebola virus infection [41] . The exact mechanism of apparent benefit of these drugs in coronavirus infection is not yet clear. However, there could be several explanations [42] .
i. Increased ACE2 expression may not result in more viral entry into the cell because of the limited availability of the serine protease TMPRSS2. Camostat mesylate, which is a TMPRSS2 inhibitor, has been shown to inhibit cellular entry of SARS CoV2 and could be a potential therapeutic option [43] .
ii. Increased ACE2 expression on the cell membrane may also lead to increased soluble ACE2 in blood, which may actually bind to most of SARS CoV2 and prevent its interaction with the membrane bound receptor.
iii. RAS blockers increase angiotensin II, which is a substrate for ACE2. The interaction of ACE2 with angiotensin II could induce a conformational change in the receptor binding domain of ACE2, limiting its ability to bind with SARS CoV2 [44] .
iv. ACE2 receptors are present at a much higher density in lung tissue of children and young adults, compared to older individuals. Thus, the upregulation of ACE2 receptors by the use of RASB over time in older people may emulate ACE expression in young people. It is also possible that having more ACE2 receptors and increased ACE2 functions will likely produce more angiotensin (1-7) that might provide resilience against target-mediated destruction and development of pulmonary failure in patients with COVID-19 [22] . This postulated positive effects on lung can be also protective during overwhelming infection with COVID-19.
v. Indiscriminate discontinuation of RASB in patients with heart failure may also lead to readmission to hospital and increase in mortality [45] .
Collectively, relationship between RAS activity and use of RASB in SARS CoV2
infection is very scarce. The only indirect evidence of RAS activation in COVID-19 is high incidence of hypokalaemia [46] . With regards to the use of RASB, a retrospective analysis of 112 COVID-19 hospitalised patients with cardiovascular disease in Wuhan, there was no significant difference in the proportion of ACEI/ARB medication between non-survivors and survivors [47] . However, a study of 187 patient reported by Guo et al, there was a trend of increase in mortality in patients with COVID-19 receiving RASB (36.8%), compared to those not receiving (25.6%) [14] .
Conclusion:
COVID-19 is increasingly associated with comorbidities that include hypertension and diabetes. Special care is also required in patients with COVID-19 with associated comorbidities, given the heightened risk of in-hospital death.
In view of lack of robust evidence for either benefit or harm, and with bulk of the experimental evidence in favour of benefit, it is reasonable for patients to continue using ACE inhibitors and ARB, as recommended by the European Society of Cardiology, Hypertension Canada, The Canadian Cardiovascular Society, UK Renal Association, the International Society of Hypertension, and European Society of Hypertension and American Heart Association [48] [49] [50] . Future studies reporting the outcome stratified on the basis of different anti-hypertensive agents in COVID-19 may further enlighten us in this regard.
